|
|
|
|
| LEADER |
05333cam a2200625Ii 4500 |
| 001 |
1090139178 |
| 003 |
OCoLC |
| 005 |
20190427054234.1 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
190319s2019 ne o 001 0 eng d |
| 019 |
|
|
|a 1090441504
|a 1090545837
|a 1090758989
|a 1090853090
|
| 020 |
|
|
|a 9780128166291
|q (electronic bk.)
|
| 020 |
|
|
|a 0128166290
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128165058
|q (print)
|
| 020 |
|
|
|z 0128165057
|
| 035 |
|
|
|a (OCoLC)1090139178
|z (OCoLC)1090441504
|z (OCoLC)1090545837
|z (OCoLC)1090758989
|z (OCoLC)1090853090
|
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d N$T
|d EBLCP
|d YDX
|
| 049 |
|
|
|a COM6
|
| 050 |
|
4 |
|a R857.N34
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.6
|2 23
|
| 245 |
0 |
0 |
|a Nanomaterials for drug delivery and therapy /
|c edited by Alexandru Mihai Grumezescu.
|
| 264 |
|
1 |
|a Amsterdam, Netherlands :
|b Elsevier,
|c 2019.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent.
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia.
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier.
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover; Nanomaterials for Drug Delivery and Therapy; Copyright Page; Contents; List of Contributors; Foreword; Preface; 1 Cell and organ drug targeting; 1.1 Introduction; 1.2 Why Targeting Cell and Organ Is Required?; 1.3 Strategies for Drug Targeting; 1.3.1 Passive Targeting; 1.3.2 Inverse Targeting; 1.3.3 Active Targeting; 1.3.3.1 First order targeting; 1.3.3.2 Second order targeting; 1.3.3.3 Third order targeting; 1.3.3.4 Ligand mediated targeting; 1.3.4 Physical Targeting; 1.3.5 Dual Targeting; 1.3.6 Double Targeting; 1.4 Carriers for Drug Targeting.
|
| 505 |
8 |
|
|a 1.4.1 The Microparticles: Microspheres and Microcapsules1.4.1.1 Application of microparticles as a carrier for targeted drug delivery; 1.4.1.1.1 Ophthalmic drug delivery; 1.4.1.1.2 Gene delivery; 1.4.1.1.3 Drug delivery for anticancer therapy; 1.4.1.1.4 Vaginal drug delivery; 1.4.1.2 Pros and cons of microparticulate delivery system; 1.4.2 Nanocarriers; 1.4.2.1 Vital nanocarriers; 1.4.2.2 Application of nanoparticles as a carrier for targeted drug delivery; 1.4.2.2.1 Intratumoral drug delivery; 1.4.2.2.2 Intrahepatic drug delivery; 1.4.2.2.3 Intracellular drug delivery.
|
| 505 |
8 |
|
|a 1.4.2.2.4 Targeted drug delivery to the brain1.4.2.3 Pros and cons of nanocarriers; 1.4.3 Vesicular Carriers; 1.4.3.1 Liposomes; 1.4.3.1.1 Application of liposomes; 1.4.3.2 Niosomes; 1.4.3.2.1 Application of niosomes as a carrier for targeted drug delivery; 1.4.3.3 Ufasomes; 1.4.3.3.1 Application of ufasomes as a carrier for targeted drug delivery; 1.4.3.4 Pharmacosomes; 1.4.3.4.1 Application of pharmacosome in targeted delivery; 1.4.3.5 Virosomes; 1.4.3.5.1 Application of virosomes in targeted drug delivery; 1.4.3.6 Cubosomes; 1.4.3.6.1 Application of cubosomes in targeted drug delivery.
|
| 505 |
8 |
|
|a 1.4.3.7 Pros and cons of vesicular carriers1.4.4 Cells as the Carriers for Targeted Drug Delivery; 1.4.4.1 Neutrophils; 1.4.4.2 Lymphocytes; 1.4.4.3 Fibroblasts; 1.4.4.4 Artificial cells; 1.4.4.5 Resealed erythrocytes; 1.4.4.6 Nanoerythrosomes; 1.4.4.7 Pros and cons of cell-based carriers; 1.4.5 Miscellaneous Carrier Systems; 1.4.5.1 Quantum dot; 1.4.5.2 Prodrug(s); 1.4.5.3 Monoclonal antibodies; 1.5 Future Perspectives; References; 2 Characterization of pharmaceutical nanocarriers: in vitro and in vivo studies; 2.1 Introduction; 2.2 Characterization; 2.2.1 In Vitro Parameters.
|
| 505 |
8 |
|
|a 2.2.1.1 Presence of nanocarriers2.2.1.2 Size; 2.2.1.2.1 Photon correlation spectroscopy; 2.2.1.2.2 Transmission electron microscopy; 2.2.1.2.3 Laser diffraction study; 2.2.1.2.4 Turbidity method; 2.2.1.2.5 Nuclear magnetic resonance; 2.2.1.2.6 Filtration; 2.2.1.2.7 Optical microscopy; 2.2.1.3 Morphology; 2.2.1.3.1 Electron microscopy; 2.2.1.3.2 Atomic force microscopy; 2.2.1.4 Zeta potential; 2.2.1.5 Surface hydrophobicity; 2.2.1.5.1 Hydrophobic interaction chromatography; 2.2.1.6 Entrapment/incorporation efficiency; 2.2.1.7 Drug content; 2.2.1.8 Solubility study.
|
| 650 |
|
0 |
|a Nanostructured materials
|x Therapeutic use.
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
7 |
|a MEDICAL / Pharmacology.
|2 bisacsh.
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Grumezescu, Alexandru Mihai,
|e editor.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 776 |
0 |
8 |
|i Print version:
|a Grumezescu, Alexandru Mihai, author.
|t Nanomaterials for drug delivery and therapy
|z 9780128165058
|w (OCoLC)1085965515.
|
| 907 |
|
|
|a .b5948911x
|b multi
|c -
|d 190429
|e 230213
|
| 998 |
|
|
|a cue
|a cu
|b 190429
|c m
|d z
|e -
|f eng
|g ne
|h 0
|i 1
|
| 948 |
|
|
|a MARCIVE Overnight, in 2023.02
|
| 948 |
|
|
|a MARCIVE Comp, 2019.12
|
| 948 |
|
|
|a MARCIVE Overnight 05/2019
|
| 994 |
|
|
|a 92
|b COM
|
| 995 |
|
|
|a Loaded with m2btab.ltiac in 2023.02
|
| 995 |
|
|
|a Loaded with m2btab.ltiac in 2019.12
|
| 995 |
|
|
|a Loaded with m2btab.ltiac in 2019.05
|
| 995 |
0 |
0 |
|a OCLC offline update by CMU and loaded with m2btab.elec in 2019.04
|
| 989 |
|
|
|d cueme
|e - -
|f - -
|g j
|h 0
|i 0
|j 188
|k 190429
|l $0.00
|m
|n - -
|o -
|p 0
|q 0
|t 0
|x 0
|w Elsevier
|1 .i125228168
|u http://ezproxy.coloradomesa.edu/login?url=https://www.sciencedirect.com/science/book/9780128165058
|3 Elsevier
|z Click here for access
|